Subhash

These days, everyone is highly conscious of the use of toothpaste. There are medicinal and herbal toothpastes on the market right now. There is fierce competition among toothpaste manufacturers to produce better formulas that can stave off dental issues. Chewable tablets that must be broken and licked between the teeth in order to be consumed. These tablets are used to people who find swallowing unpleasant as well as youngsters who have trouble swallowing.  Chewable tablets are characterized by their smooth breakdown, agreeable flavor, and absence of bitter or unpleasant aftertaste. Chewable tablets are an ideal dosage form for individuals who are elderly, young, or traveling and may not always have access to water. The gum core, which may or may not be coated, makes up the content of a chewable tablet. An insoluble gum foundation made up of fillers, antioxidants, sweeteners, and flavoring ingredients makes up the core.  It is flavored with something to improve its taste. There are several components that go into making chewable pills. The main formulation factors that apply to both regular (swallowed) and chewable tablets include flow, lubrication, disintegration, organoleptic qualities, compressibility, compatibility, and stability; however, the main focus of this formulation is on the organoleptic features of the active drug components.  The purpose of this review article is to investigate dental issues with sparing on a modified tablet dosage form, such as a toothpaste tablet, which will help to reduce plastic waste and be more affordable, eco-friendly, and beneficial to dental health.

Candesartan cilexetil is an antihypertensive drug effective for the treatment of hypertension and heart failure. The main goal is to formulate and evaluate the sustained release matrix tablets of candesartan cilexetil using different polymers like hydrophilic and hydrophobic. Different formulations were prepared by direct compression method using various release retarding polymers like carbopol 934P, HPMC K15M, sod.CMC. Water soluble surfactant SLS was employed for enhancing the solubility of candesartan cilexetil. Drug-excipients compatibility was carried out by FTIR. Different formulations were evaluated for hardness, thickness, friability, drug content and in vitro drug release. The results were found to be satisfactory in terms of physico-chemical parameters. The F10 formulation was found to display highest drug release of drug. Mathematical analysis of the release kinetics was carried out to determine the mechanism of drug release. In vitro release data was fitted into various models to ascertain the kinetic of drug release.

Marine Streptomyces sp.T1027 obtained from South coast of India was discovered to produce and accumulate β-carotene under the influence of light in liquid shake flask culture. The accumulation of β-carotene was growth associated and controlled by light, aeration, carbon and substrate solubility. Starch was the ideal substrate for maximum growth (4.5-6.1 g l-1) and β-carotene accumulation (92-130 μg g-1). Rapid extraction was done in Dimethylsulphoxide, Methanol (1:1) Solvent mixture. The organism was sensitive to a variety of antibiotics; in turn it was able to inhibit the human pathogen Corynebacterium diphtheria. Commercial substrates with high soluble starch content were found to produce maximum biomass and β-carotene production.

A simple, precise, accurate and stability-indicating reverse phase high performance liquid chromatography (RP-HPLC) method is developed for estimation of Levosalbutamol sulphate and Budesonide in bulk and suspension for inhalation dosage form. The method employed, with reverse phase Inertsil® 5μ C18 (250 × 4.0 mm) column in an isocratic mode, with mobile phase of acetonitrile: buffer in the ratio 40:60 (%v/v). The flow rate was 0.8 ml/min and effluent was monitored at 266 nm. Retention time was found to be 3.16 min., 17.94 min. and 20.90 min. The method was validated in terms of linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ) etc. in accordance with ICH guidelines. Linear regression analysis data for the calibration plot showed that there was good linear relationship between response and concentration in the range of 25 – 150% of the working concentration (r2 > 0.999) respectively. The LOD and LOQ values for were found to be 0.43, 0.72, 0.97 and 1.24 µg/ml respectively. No chromatographic interference from placebo and degradants were found. The proposed method was successfully used for estimation of Levosalbutamol sulphate and Budesonide in bulk and suspension for inhalation dosage forms.

The present paper describes the development and validation of novel chiral HPLC method for the enantiomeric separation of S-Levosimendan from R-Levosimendan and quantitative determination of S-Levosimendan enantiomer in Levosimendan bulk drugs. The enantiomers of levosimendan were baseline resolved on normal phase chromatographic separation on Amylose tris (3,5-dimethylphenylcarbamate) immobilized on 5μm silica-gel-Based Chiral Stationary Phase, Chiral pak IA column (250mm ×4.6mm i.d.; particle size,5μ) at a temperature of 30°C using a mobile phase consisting of MTBE:Ethanol:TFA (650 : 350 : 1.0, v/v/v) at a flow rate of 1.0mLmin-1 with an injection volume of 10μL. Quantitation was achieved with UV detection at 383nm based on peak area with linear calibration curves. The elution times of S-Levosimendan and R-Levosimendan were 6.8 min and 11.0 minutes respectively. In this proposed chiral HPLC method, the resolution between S-Levosimendan and R-Levosimendan was found to be greater than 8.0. The developed method was validated with respect to linearity, accuracy, precision, solution stability, ruggedness, robustness, limit of detection and limit of quantification. The recovery obtained for S-isomer was in between 99.1 % and 107.9%. The detection limit obtained for S-isomer was 0.025μg.mL-1 and the quantification limit was 0.075μg.mL-1 respectively. Linearity was performed for the S-isomer from LOQ to 150%. The correlation coefficient obtained for S-isomer was more than 0.999. The solution stability of Levosimendan bulk drug was determined and the compound was found to be stable up to 48 hrs. As the method has less run time (20 min), it can be useful in quality control laboratories for routine analysis.